Share on StockTwits

DexCom (NASDAQ:DXCM) SVP Andrew K. Balo sold 20,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $44.24, for a total value of $884,800.00. Following the sale, the senior vice president now directly owns 159,205 shares of the company’s stock, valued at approximately $7,043,229. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of research firms have recently commented on DXCM. Analysts at Zacks reiterated a “neutral” rating on shares of DexCom in a research note on Friday, August 8th. They now have a $46.00 price target on the stock. Separately, analysts at Raymond James reiterated an “outperform” rating on shares of DexCom in a research note on Thursday, August 7th. They now have a $46.00 price target on the stock, up previously from $44.00. Finally, analysts at Canaccord Genuity raised their price target on shares of DexCom from $40.00 to $48.00 in a research note on Thursday, August 7th. They now have a “buy” rating on the stock. One research analyst has rated the stock with a sell rating, five have given a hold rating and seven have issued a buy rating to the company. DexCom has a consensus rating of “Hold” and a consensus target price of $41.00.

DexCom (NASDAQ:DXCM) traded down 0.39% on Monday, hitting $43.91. 364,197 shares of the company’s stock traded hands. DexCom has a 52 week low of $25.49 and a 52 week high of $49.83. The stock has a 50-day moving average of $39.89 and a 200-day moving average of $38.97. The company’s market cap is $3.314 billion.

DexCom (NASDAQ:DXCM) last announced its earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.10) by $0.01. The company had revenue of $58.80 million for the quarter, compared to the consensus estimate of $52.45 million. During the same quarter last year, the company posted ($0.14) earnings per share. DexCom’s revenue was up 64.2% compared to the same quarter last year. Analysts expect that DexCom will post $-0.32 EPS for the current fiscal year.

DexCom, Inc (NASDAQ:DXCM) is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers in the hospital for the treatment of both diabetic and non-diabetic patients.

Receive News & Ratings for DexCom Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.